Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen

Henriksen‐Lacey, Malou; Bramwell, Vincent W.; Christensen, Dennis; Agger, Else Marie; Andersen, Peter; Perrie, Yvonne

doi:10.1016/j.jconrel.2009.10.022

Cited by 174 publications

(179 citation statements)

References 25 publications

Supporting

Mentioning

165

Contrasting

Unclassified

Order By: Relevance

“…Newer studies with the cationic liposome formulation dimethyl dioctadecylammonium (DDA) plus trehalose dibehenate (TDB) (DDA/ TDB, CAF01) showed no differences in liposome draining or antigen release from the injection site. However, differences in movement to regional lymph nodes (LNs) were noted [Henriksen-Lacey et al 2010. A cationic liposome pDNA vaccine of 500 nm and 140 nm size with encapsulated ovalbumin (OVA) encoding pDNA as antigen showed strongest retention at large vesicle size.…”

Section: Liposome-based Antigensmentioning

confidence: 99%

Liposomes as vaccine delivery systems: a review of the recent advances

Schwendener

2014

Therapeutic Advances in Vaccines

440

309

View full text Add to dashboard Cite

Liposomes and liposome-derived nanovesicles such as archaeosomes and virosomes have become important carrier systems in vaccine development and the interest for liposome-based vaccines has markedly increased. A key advantage of liposomes, archaeosomes and virosomes in general, and liposome-based vaccine delivery systems in particular, is their versatility and plasticity. Liposome composition and preparation can be chosen to achieve desired features such as selection of lipid, charge, size, size distribution, entrapment and location of antigens or adjuvants. Depending on the chemical properties, water-soluble antigens (proteins, peptides, nucleic acids, carbohydrates, haptens) are entrapped within the aqueous inner space of liposomes, whereas lipophilic compounds (lipopeptides, antigens, adjuvants, linker molecules) are intercalated into the lipid bilayer and antigens or adjuvants can be attached to the liposome surface either by adsorption or stable chemical linking. Coformulations containing different types of antigens or adjuvants can be combined with the parameters mentioned to tailor liposomal vaccines for individual applications. Special emphasis is given in this review to cationic adjuvant liposome vaccine formulations. Examples of vaccines made with CAF01, an adjuvant composed of the synthetic immune-stimulating mycobacterial cordfactor glycolipid trehalose dibehenate as immunomodulator and the cationic membrane forming molecule dimethyl dioctadecylammonium are presented. Other vaccines such as cationic liposome-DNA complexes (CLDCs) and other adjuvants like muramyl dipeptide, monophosphoryl lipid A and listeriolysin O are mentioned as well. The field of liposomes and liposome-based vaccines is vast. Therefore, this review concentrates on recent and relevant studies emphasizing current reports dealing with the most studied antigens and adjuvants, and pertinent examples of vaccines. Studies on liposome-based veterinary vaccines and experimental therapeutic cancer vaccines are also summarized.

show abstract

Section: Liposome-based Antigensmentioning

confidence: 99%

Liposomes as vaccine delivery systems: a review of the recent advances

Schwendener

2014

Therapeutic Advances in Vaccines

440

309

View full text Add to dashboard Cite

show abstract

“…[1][2][3][4][5] Wide interest in CLs stems from their unique attributes, including their abilities to form nanocomplexes with anionic plasmid DNAs, peptides, and proteins; 1,2 to prolong antigen release at the site of injection (ie, depot effect); 6,7 to induce uptake by antigen-presenting cells (APCs) mediated by their ionic interaction with negatively charged cellular membranes; 1,8 and to allow the simultaneous delivery of antigen and adjuvant molecules to APCs, including B-cells, for the induction of IgG responses. [9][10][11] Importantly, CLs can also enhance antigen cross-presentation 12,13 -the process by which APCs phagocytose extracellular protein antigens, process them intracellularly into peptide epitopes, and present them in the context of major histocompatibility complex-I (MHC-I) on the The specialized role of DCs in cross-presentation is supported by their unique characteristics, including their mildly degradative phagosomes compared to those of other phagocytic cells, such as macrophages; shuttling of endosomal protein antigens to the cytosol for subsequent processing via proteasomes for antigen degradation; and efficient loading of the processed antigen peptides onto MHC-I molecules via either endoplasmic reticulum (ER) or vacuolar endosomal pathways.…”

Section: Introductionmentioning

confidence: 99%

“…After centrifugation, cells were seeded into nontissue culture-treated Petri dish at a density of 2×10 6 cells/ dish and cultured in DC culture media (RPMI 1640 supplemented with 10% FBS, 1% penicillin-streptomycin, 50 μM β-mercaptoethanol, and 20 ng/mL GM-CSF) at 37°C with 5% CO 2 . Culture media were refreshed on days 3, 6, and 8, and BMDCs were used on days 10-12.…”

mentioning

confidence: 99%

Cationic liposomes promote antigen cross-presentation in dendritic cells by alkalizing the lysosomal pH and limiting the degradation of antigens

Gao¹,

Ochyl²,

Yang³

et al. 2017

IJN

View full text Add to dashboard Cite

Cationic liposomes (CLs) have been widely examined as vaccine delivery nanoparticles since they can form complexes with biomacromolecules, promote delivery of antigens and adjuvant molecules to antigen-presenting cells (APCs), and mediate cellular uptake of vaccine components. CLs are also known to trigger antigen cross-presentation – the process by which APCs internalize extracellular protein antigens, degrade them into minimal CD8 + T-cell epitopes, and present them in the context of major histocompatibility complex-I (MHC-I). However, the precise mechanisms behind CL-mediated induction of cross-presentation and cross-priming of CD8 + T-cells remain to be elucidated. In this study, we have developed two distinct CL systems and examined their impact on the lysosomal pH in dendritic cells (DCs), antigen degradation, and presentation of peptide:MHC-I complexes to antigen-specific CD8 + T-cells. To achieve this, we have used 3β-[ N -( N ′, N ′-dimethylaminoethane)-carbamoyl] cholesterol (DC-Chol) and 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) as the prototypical components of CLs with tertiary amine groups and compared the effect of CLs and anionic liposomes on lysosomal pH, antigen degradation, and cross-presentation by DCs. Our results showed that CLs, but not anionic liposomes, elevated the lysosomal pH in DCs and reduced antigen degradation, thereby promoting cross-presentation and cross-priming of CD8 + T-cell responses. These studies shed new light on CL-mediated cross-presentation and suggest that intracellular fate of vaccine components and subsequent immunological responses can be controlled by rational design of nanomaterials.

show abstract

“…36 Using this method we were able to demonstrate that while antigen delivered without liposomes were removed quickly from the body, liposomes based on DDA promoted a depot at the injection site (both after subcutaneous or intramuscular injection) and that TDB did not significantly influence this deport effect. 37 However, the presence of TDB in the DDA liposomes increased the influx of monocytes to the site of injection, and the subsequent draining of the liposomal adjuvant to the popliteal lymph nodes, in addition to inducing a powerful Th1 response. 37 The impact on vesicle charge on the deposition of antigen at the injection site was further considered by comparing cationic DDA:TDB liposomes with a comparable near-neutral liposome formulation composed of Distearoylphosphatidylcholine (DSPC) and TDB (11 mol%).…”

Section: The Impact Of Lipid Choicethe Controlling Role Of Chargementioning

confidence: 99%

“…37 However, the presence of TDB in the DDA liposomes increased the influx of monocytes to the site of injection, and the subsequent draining of the liposomal adjuvant to the popliteal lymph nodes, in addition to inducing a powerful Th1 response. 37 The impact on vesicle charge on the deposition of antigen at the injection site was further considered by comparing cationic DDA:TDB liposomes with a comparable near-neutral liposome formulation composed of Distearoylphosphatidylcholine (DSPC) and TDB (11 mol%). 38 This study demonstrates that the cationic nature of the vesicles promotes the retention of the liposomal components at the site of injection, with the DSPC:TDB formulation being more rapidly cleared.…”

Section: The Impact Of Lipid Choicethe Controlling Role Of Chargementioning

confidence: 99%